Report Content
Chapter 1 Delivery Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Central nervous system therapeutics industry 360º synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Disease trends
2.1.4 Drug type trends
2.1.5 Distribution Channel trends
Chapter 3 Central Nervous System Therapeutics Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of CNS disorders
3.2.1.2 Technological advancements in drug development
3.2.1.3 Growing geriatric population
3.2.1.4 Increasing healthcare expenditure
3.2.1.5 Growing investments in R&D
3.2.1.6 Incrasing awareness about CNS disorders
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse drug reactions and safety concerns
3.2.2.2 Stringent regulatory requirements
3.2.2.3 High development costs
3.3 Growth potential analysis
3.3.1 By disease
3.3.2 By drug type
3.3.3 By distribution channel
3.4 COVID- 19 impact analysis
3.5 Porter's analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategy dashboard, 2022
4.6 Strategic outlook matrix, 2022
Chapter 5 Central Nervous System Therapeutics Market Size and Forecast, By Disease (USD Million)
5.1 Key trends, by disease
5.2 Neurovascular diseases
5.3 Mental health
5.3.1 Anxiety disorders
5.3.2 Mood disorders
5.3.3 Epilepsy
5.3.4 Psychotic disorders
5.3.5 Other mental health disorders
5.4 Degenerative disorders
5.4.1 Alzheimer’s disease
5.4.2 Parkinson’s disease
5.4.3 Multiple sclerosis
5.4.4 Huntington's disease
5.4.5 Amyotrophic lateral sclerosis
5.4.6 Other degenerative disorders
5.5 Genetic diseases
5.6 Substance abuse disorders
5.7 Autoimmune and inflammatory diseases
5.8 CNS trauma
5.9 Infectious diseases
5.10 CNS cancer
5.11 Other diseases
Chapter 6 Central Nervous System Therapeutics Market Size and Forecast, By Drug type (USD Million)
6.1 Key trends, by drug type
6.2 Analgesics
6.3 Antidepressant
6.4 Anesthetics
6.5 Anti-parkinson drugs
6.6 Anti-epileptics
6.7 Decarboxylase inhibitors
6.8 Dopamine agonists
6.9 Immunomodulatory drug
6.10 Interferons
6.11 Other drug classes
Chapter 7 Central Nervous System Therapeutics Market Size and Forecast, By Distribution Channel (USD Million)
7.1 Key trends, by distribution channel
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Other distribution channels
Chapter 8 Central Nervous System Therapeutics Market Size and Forecast, By Region (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East & Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 Biogen
9.2 Otsuka Pharmaceutical Co., Ltd.
9.3 Eli Lilly and Company
9.4 Merck & Co.
9.5 Astra Zeneca
9.6 Shire PLC
9.7 Novartis AG
9.8 Teva Pharmaceutical Industries Ltd.
9.9 Johnson & Johnson Services, Inc.
9.10 Pfizer, Inc.
